Janux Therapeutics has dosed the first participant in a Phase I clinical trial of JANX011, a Cluster of Differentiation 19 ...
The MarketWatch News Department was not involved in the creation of this content. A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data ...
Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...
Immunotherapy has transformed the field of medicine. In the context of cancer, immune cells become dysregulated and lose the ...
Adaptive Biotechnologies (NASDAQ:ADPT) executives said the company delivered “remarkable” performance in 2025, driven by ...
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results